Motixafortide

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Motixafortide is a drug catalogued in DrugCentral. It was first approved by the FDA in 2023. DrugCentral lists 1 molecular target, including CXCR4. Recorded indications include Mobilize hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.

• Molecular targets: CXCR4 (1 listed in DrugCentral).
• Indications: Mobilize hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.
• ATC code: L03AX23 (Other immunostimulants).
• Molecular formula: C97H144FN33O19S2; molecular weight 2159.56 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Mobilize hematopoietic stem cells for autologous transplantation in patients with multiple myeloma

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
C-X-C chemokine receptor type 4	CXCR4	antagonist	Kd 11.10

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2023-09-08	FDA	—	BIOLINERX, LTD.	Yes

ATC classification

ATC code	Therapeutic hierarchy
L03AX23	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSTIMULANTS › IMMUNOSTIMULANTS › Other immunostimulants

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Injection site pain	126.5

Chemical structure

• Molecular formula: C₉₇H₁₄₄FN₃₃O₁₉S₂
• Molecular weight: 2159.56 g/mol
• CAS number: —
• InChIKey: PJCFOQMKZQWVAL-KZGZZEQFSA-N
• PubChem CID: 91865076

NCCCC[C@@H]1NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC2=CC=C(O)C=C2)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](CCCCN)NC1=O)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CC1=CC=CC2=CC=CC=C12)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)C1=CC=C(F)C=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Motixafortide used for?

DrugCentral lists the following indications for Motixafortide: Mobilize hematopoietic stem cells for autologous transplantation in patients with multiple myeloma.

How does Motixafortide work?

Its molecular targets in DrugCentral include CXCR4 (antagonist).

When was Motixafortide first approved?

Motixafortide was first approved by the FDA in 2023.

What is the chemical formula of Motixafortide?

Motixafortide has the molecular formula C97H144FN33O19S2 and a molecular weight of 2159.56 g/mol.

Sources

• DrugCentral drug card 5744 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL5095030 — compound record and bioactivity
• PubChem CID 91865076 — chemical identifiers
• DrugBank DB14939 — drug record
• FDA UNII DA9G065962 — substance identity
• DailyMed: FDA labels for Motixafortide — current prescribing information (label search)
• UniProt P61073 (CXCR4) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.